Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial
Theodore D.K. Chung MD, PhD
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois
Department of Radiation Oncology, University of Illinois at Chicago, Chicago, Illinois
Search for more papers by this authorIrwin I. Park
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois
Search for more papers by this authorLani Ignacio BSN
Department of Radiation Oncology, Michael Reese Hospital and Medical Center, Chicago, Illinois
Search for more papers by this authorRose Catchatourian MD
Division of Hematology–Oncology, Michael Reese Hospital and Medical Center, Chicago, Illinois
Search for more papers by this authorMitchell Kopnick MD
Division of Urology, Michael Reese Hospital and Medical Center, Chicago, Ilinois
Search for more papers by this authorEvelyn Davison
Department of Radiation Oncology, Michael Reese Hospital and Medical Center, Chicago, Illinois
Search for more papers by this authorGeraldine Conrad
Office of Public Relations, Michael Reese Hospital and Medical Center, Chicago, Ilinois
Search for more papers by this authorAzhar M. Awan MD
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois
Department of Radiation Oncology, LaGrange Memorial Hospital, LaGrange, Ilinois
Search for more papers by this authorCorresponding Author
Srinivasan Vijayakumar MD
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois
Department of Radiation Oncology, University of Illinois at Chicago, Chicago, Illinois
Department of Radiation Oncology, Michael Reese Hospital and Medical Center, Chicago, Illinois
Southwest Oncology Group, San Antonio, Texas
Department of Radiation Oncology, University of Illinois at Chicago, 1800 West Taylor Street, MC933, Chicago, IL 60612. Phone: (312) 996-3630; Fax: (312) 413-3068Search for more papers by this authorTheodore D.K. Chung MD, PhD
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois
Department of Radiation Oncology, University of Illinois at Chicago, Chicago, Illinois
Search for more papers by this authorIrwin I. Park
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois
Search for more papers by this authorLani Ignacio BSN
Department of Radiation Oncology, Michael Reese Hospital and Medical Center, Chicago, Illinois
Search for more papers by this authorRose Catchatourian MD
Division of Hematology–Oncology, Michael Reese Hospital and Medical Center, Chicago, Illinois
Search for more papers by this authorMitchell Kopnick MD
Division of Urology, Michael Reese Hospital and Medical Center, Chicago, Ilinois
Search for more papers by this authorEvelyn Davison
Department of Radiation Oncology, Michael Reese Hospital and Medical Center, Chicago, Illinois
Search for more papers by this authorGeraldine Conrad
Office of Public Relations, Michael Reese Hospital and Medical Center, Chicago, Ilinois
Search for more papers by this authorAzhar M. Awan MD
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois
Department of Radiation Oncology, LaGrange Memorial Hospital, LaGrange, Ilinois
Search for more papers by this authorCorresponding Author
Srinivasan Vijayakumar MD
Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois
Department of Radiation Oncology, University of Illinois at Chicago, Chicago, Illinois
Department of Radiation Oncology, Michael Reese Hospital and Medical Center, Chicago, Illinois
Southwest Oncology Group, San Antonio, Texas
Department of Radiation Oncology, University of Illinois at Chicago, 1800 West Taylor Street, MC933, Chicago, IL 60612. Phone: (312) 996-3630; Fax: (312) 413-3068Search for more papers by this author
REFERENCES
- 1Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995; 16: 150–163.
- 2Lee MM, Chamberlain R, Catchatourian R, Jiang H, Kopnick M, Ray P, Vijayakumar S. Social factors as predictors of interest in participating in a prostate chemoprevention trial. J Cancer Ed 1999; 14: 88–92.
- 3Eisner E, Tobin E. What should we tell men about prostate cancer? Focus group research to help develop a communications strategy on prostate cancer for older men. Bethesda, MD: Office of Cancer Communications, National Cancer Institute, October, 1992.
- 4Demark-Wahnefried W, Strigo T, Catoe K, Conaway M, Brunetti M, Rimer BK, Robertson CN. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology 1995; 46: 346–351.
- 5Herxheimer A, Lundberg CS, Westerholm B. Advertisements for medicines in leading journals in 18 countries: a 12 month survey of information content and standards. Int J Health Serv 1993; 23: 161–172.
- 6Krupka LR, Vener AM. Prescription drug advertising: trends and implications. Soc Sci Med 1985; 20: 191–197.
- 7Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: expert assessments. Ann Int Med 1992; 116: 912–919.
- 8Wofford JL, Pinson JA, Follmar SJ, Moran WP. Health related messages in consumer magazine advertising. J Gen Int Med 1995; 10: 488–490.
- 9Roberson NN. Clinical trial participation. Cancer 1994; 74: 2687–2691.
10.1002/1097-0142(19941101)74:9+<2687::AID-CNCR2820741817>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- 10Bang KM, White JE, Gause BL, Leffall LD Jr. Evaluation of recent trends in cancer mortality and incidence among blacks. CA Cancer J Clin 1988; 61: 1255–1261.
10.1002/1097-0142(19880315)61:6<1255::AID-CNCR2820610634>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 11Hollis JF, Satterfield S, Smith F, Fouad M, Allender PS, Borhani N, Charleston J, Hirlinger M, King N, Schultz R, et al. Recruitment for phase II of the Trials of Hypertension Prevention. Effective strategies and predictors of randomization. Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol 1995; 5: 140–148.
Citing Literature
